title: Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE.
abstract: BACKGROUND
  A growing body of evidence supports the hypothesis that vitamin D is an important environmental factor in the etiology of T-cell-mediated autoimmune diseases such as multiple sclerosis (MS).
  
  
  OBJECTIVE
  The purpose of this study was exploring the mechanisms underlying the beneficial effect of vitamin D3 in encephalomyelitis (EAE).
  
  
  METHODS
  We treated monophasic experimental autoimmune EAE, induced in Lewis rat, with vitamin D3 and adoptively transfer tolerogenic bone marrow-derived DCs generated in the presence of vitamin D3.
  
  
  RESULTS
  This study provides evidence that the in vivo administration of vitamin D3, as well as the adoptive transfer of vitamin D3 -induced IDO(+) immature/tolerogenic dendritic cells, leads to a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) regulatory T cells in the lymph nodes in a rat model of MS, experimental autoimmune EAE. Concomitant with the increase in this cell population, there is a significant decrease in the number of autoreactive T cells in the central nervous system. Bone marrow-derived DCs cultivated in the presence of vitamin D3 present a tolerogenic profile with high IL-10, TNFα, and IDO expression and decreased MHC-II and CD80 expression. The adoptive transfer of IDO (+) DCs induces a significant increase in the percentage of CD4(+) CD25(+) Foxp3(+) T cells in the lymph nodes, comparable with vitamin D3 treatment.
  
  
  CONCLUSIONS
  These mechanisms contribute actively to the generation of a microenvironment in the lymph nodes that suppresses the activation of encephalitogenic T cells, resulting in the downregulation of the inflammatory response in the central nervous system.
authors.affiliation: Neuroimmunology Unit, Department of Genetics, Evolution and Bioagents, University of Campinas (UNICAMP), Campinas, SP, Brazil.
authors.forename: Alessandro S
authors.initials: AS
authors.lastname: Farias
authors.forename: Gabriela S
authors.initials: GS
authors.lastname: Spagnol
authors.forename: Pedro
authors.initials: P
authors.lastname: Bordeaux-Rego
authors.forename: Camila O F
authors.initials: CO
authors.lastname: Oliveira
authors.forename: Ana Gabriela M
authors.initials: AG
authors.lastname: Fontana
authors.forename: Rosemeire F O
authors.initials: RF
authors.lastname: de Paula
authors.forename: Mariana P A
authors.initials: MP
authors.lastname: Santos
authors.forename: Fernando
authors.initials: F
authors.lastname: Pradella
authors.forename: Adriel S
authors.initials: AS
authors.lastname: Moraes
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Oliveira
authors.forename: Ana Leda F
authors.initials: AL
authors.lastname: Longhini
authors.forename: Alexandre C S
authors.initials: AC
authors.lastname: Rezende
authors.forename: Mauro W
authors.initials: MW
authors.lastname: Vaisberg
authors.forename: Leonilda M B
authors.initials: LM
authors.lastname: Santos
mesh_terms: D000818:Animals; D002762:Cholecalciferol / Q000494:pharmacology* / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D051381:Rats; D011917:Rats, Inbred Lew; D012720:Severity of Illness Index; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology / Q000473:pathology
chemical_list: D002762:Cholecalciferol